U.S. patent application number 14/497011 was filed with the patent office on 2015-07-16 for methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water.
The applicant listed for this patent is Dow Pharmaceutical Sciences, Inc.. Invention is credited to Haigang Chen, Meidong Yang.
Application Number | 20150196536 14/497011 |
Document ID | / |
Family ID | 40913157 |
Filed Date | 2015-07-16 |
United States Patent
Application |
20150196536 |
Kind Code |
A1 |
Yang; Meidong ; et
al. |
July 16, 2015 |
METHODS AND COMPOSITIONS FOR INCREASING SOLUBILITY OF AZOLE DRUG
COMPOUNDS THAT ARE POORLY SOLUBLE IN WATER
Abstract
The combination of any two of a polyol, a polyol ether, and a
low carbon organic alcohol provides a synergistic effect on the
solubility of azole compounds, such as metronidazole, in aqueous
fluid.
Inventors: |
Yang; Meidong; (Richmond,
CA) ; Chen; Haigang; (Edina, MN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Dow Pharmaceutical Sciences, Inc. |
Petaluma |
CA |
US |
|
|
Family ID: |
40913157 |
Appl. No.: |
14/497011 |
Filed: |
September 25, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13855034 |
Apr 2, 2013 |
8877792 |
|
|
14497011 |
|
|
|
|
12928306 |
Dec 8, 2010 |
8658678 |
|
|
13855034 |
|
|
|
|
12012413 |
Feb 2, 2008 |
7893097 |
|
|
12928306 |
|
|
|
|
Current U.S.
Class: |
514/398 |
Current CPC
Class: |
A61P 17/00 20180101;
A61K 31/415 20130101; A61P 29/00 20180101; A61P 31/00 20180101;
A61K 9/06 20130101; A61K 47/10 20130101; A61P 31/10 20180101; A61P
33/02 20180101; A61P 17/10 20180101; A61K 9/10 20130101; A61K
9/0034 20130101; A61P 17/02 20180101; A61K 47/08 20130101; A61K
31/4164 20130101; A61K 9/0014 20130101; A61K 47/26 20130101; A61K
31/44 20130101 |
International
Class: |
A61K 31/4164 20060101
A61K031/4164; A61K 47/10 20060101 A61K047/10 |
Claims
1. (canceled)
2. A pharmaceutical composition comprising: water; an imidazole;
and at least two of a polyol, a polyol ether, and a low carbon
organic alcohol.
3. The pharmaceutical composition of claim 2, wherein the imidazole
is metronidazole.
4. The pharmaceutical composition of claim 3, wherein the
pharmaceutical composition comprises metronidazole in an amount
from about 1.25% (w/w) to about 1.5% (w/w).
5. The pharmaceutical composition of claim 2, wherein the polyol is
propylene glycol.
6. The pharmaceutical composition of claim 2, wherein the polyol
ether is diethylene glycol monoethyl ether.
7. The pharmaceutical composition of claim 2, wherein the polyol
ether is an ether of an alkylene glycol.
8. The pharmaceutical composition of claim 7, wherein the ether of
the alkyene glycol is polyethylene glycol.
9. The pharmaceutical composition of claim 8, wherein the
polyethylene glycol is polyethylene glycol 400 ("PEG 400").
10. The pharmaceutical composition of claim 2, wherein the low
carbon organic alcohol is benzyl alcohol.
11. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition comprises benzyl alcohol in an amount of
about 1% (w/w).
12. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition comprises benzyl alcohol in an amount of
about 2% (w/w).
13. The pharmaceutical composition of claim 2, wherein the
pharmaceutical composition comprises water in an amount of at least
about 55% (w/w).
14. The pharmaceutical composition of claim 2, wherein the
pharmaceutical composition comprises each of a polyol, a polyol
ether, and a low carbon organic alcohol.
15. The pharmaceutical composition of claim 14, wherein the polyol
is propylene glycol, the polyol ether is diethylene glycol
monoethyl ether, and the low carbon organic alcohol is benzyl
alcohol.
16. A method of treating a dermatologic or mucosal disorder that is
responsive to treatment with an imidazole compound, the method
comprising applying to an area of skin or mucosa of an individual
having the dermatologic or mucosal disorder the pharmaceutical
composition of claim 2.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/855,034, filed Apr. 2, 2013, which is a
continuation of U.S. patent application Ser. No. 12/928,306, filed
Dec. 8, 2010, now U.S. Pat. No. 8,658,678, which is a continuation
of U.S. patent application Ser. No. 12/012,413, filed Feb. 2, 2008,
now U.S. Pat. No. 7,893,097.
FIELD OF THE INVENTION
[0002] The present invention pertains to the field of increasing
solubility of chemical compounds in aqueous fluids.
BACKGROUND OF THE INVENTION
[0003] Many chemical compounds, particular chemical compounds that
are useful in pharmacologic applications, are poorly soluble in
water. Such drugs may be classified according to USP-NF as being
sparingly soluble, slightly soluble, very slightly soluble, or
insoluble in water. Many of these compounds are also poorly soluble
in oils. An example of such a chemical compound includes the azole
family of drugs, which family includes metronidazole, fluconazole,
ketoconazole, itraconazole, miconazole, dimetridazole, secnidazole,
ornidazole, tinidazole, carnidazole, and panidazole.
[0004] In many situations, such drugs may be formulated as a
suspension, in which case the lack of solubility of the drug in
water and in pharmaceutical oils does not typically have a negative
impact on bioavailability. However, in situations where a solution
of the drug is desired, or where an emulsion containing the drug in
solution either in the hydrophilic or lipophilic phase of the
emulsion is desired, the lack of solubility of the drug in water
and oils provides a significant obstacle to obtaining desired
concentrations of the drug.
[0005] The need to increase the aqueous solubility of poorly water
soluble drugs that are also poorly soluble in oils is especially
critical when formulating an emulsion, such as a topical cream,
lotion, or ointment, containing such a drug. In this case, in order
to obtain a sufficiently high concentration of the drug in the
emulsion formulation as a whole, the concentration of the drug in
the aqueous phase must be sufficiently elevated to overcome the
lack of partitioning of the drug into the oil phase.
[0006] Metronidazole is an antimicrobial drug that is administered
systemically for treatment of infections with anaerobic bacteria
and protozoans, such as Trichomonas, Entamoeba, and Giardia. It is
also used topically to treat bacterial vaginosis and various forms
of acne, including acne rosacea. The aqueous solubility of
metronidazole in water at room temperature is only about 0.87% w/w.
Additionally, physically stable solutions of metronidazole in water
that can withstand exposure to cold temperatures encountered during
shipping are limited to about 0.7% w/w metronidazole. However, for
many topical applications, a concentration of 1.0% or higher is
desired.
[0007] The lack of solubility of such drugs, and the inability to
obtain sufficiently high concentrations of drugs in solution in
pharmaceutically acceptable carriers, is a serious problem in the
formulation of topical therapeutic products for the treatment of
medical conditions affecting the skin or mucosa. Such lack of
solubility is additionally a concern in the formulation of
medications for parenteral administration and for oral liquids that
are often used for children mid geriatric patients. Accordingly, a
significant need exists for a method to increase the solubility of
drugs that are poorly soluble in water, and especially those, like
azole drugs such as metronidazole, that are also poorly soluble in
pharmaceutical oils.
DETAILED DESCRIPTION OF THE INVENTION
[0008] It has been unexpectedly discovered that the combination of
any two of a polyol, a polyol ether, and a low carbon organic
alcohol provides a synergistic effect that produces an increase in
the aqueous solubility of poorly water soluble compounds such as
drugs, including poorly water soluble compounds, such as azole
drugs.
[0009] As used herein, the term "poorly soluble" when referring to
a chemical compound in relation to its solubility in water or an
oil means a chemical compound that is sparingly soluble, slightly
soluble, very slightly soluble, or insoluble in water or an oil, as
defined in U.S. Pharmacopeia and National Formulary (USP-NF).
According to this definition, solubility is stated in terms of the
parts of the solvent needed to dissolve one part of the solute. A
compound that is sparingly soluble in a particular solvent, such as
water, requires 30-100 parts of the solvent to dissolve one part of
the compound. A compound that is slightly solvent requires 100-1000
parts of the solvent. A compound that is very slightly soluble
requires 1000-10,000 parts of the solvent. A compound that is
insoluble requires more than 10,000 parts of the solvent to
dissolve one part of the solute.
[0010] As used herein, the term "polyol" is synonymous with
"polyhydric alcohol" and refers to an alcohol that contains more
than one hydroxyl group. Examples of polyols include polyether
glycols, propylene glycol, and sugar alcohols.
[0011] As used herein, the term "polyol ether" refers to an alcohol
that contains more than one hydroxyl group and an ether group.
Examples of polyol ethers include diethylene glycol monoethyl ether
(ethoxydiglycol) (Transcutol.RTM., Gattefosse Corporation, Paramus,
N.J.), ethers of pentaerythritol, ethers of alkylene glycol, ethers
of a fatty alcohol, and ethers of a sugar.
[0012] As used herein, the term "lover carbon organic alcohol"
refers to an alcohol having the formula RCH.sub.2OH, wherein R is
either H or is a straight or branched alkyl chain of 1 to 7
carbons, or having a ring structure directly connected to a
hydroxyl group or connected to a hydroxyl group by a carbon.
Examples of low carbon organic alcohols include alkyl and aryl
alcohols such as ethyl alcohol, propyl alcohol, isopropyl alcohol,
phenol, and benzyl, alcohol.
[0013] An example of such a poorly water soluble compound that is
poorly soluble in pharmaceutical oils is the drug metronidazole, a
member of the azole family of medications. This drug is utilized as
an illustration of the invention. However, it will be understood
that the description of the invention herein pertains not just to
metronidazole but to all members of the azole family of
medications, for example, fluconazole, ketoconazole, itraconazole,
miconazole, dimetridazole, secnidazole, ornidazole, tinidazole,
carnidazole, and panidazole.
[0014] In accordance with the invention, a polyol and a polyol
ether, a polyol and a low carbon organic alcohol, a polyol ether
and a low carbon organic alcohol, or a polyol, a polyol ether, and
a low carbon organic alcohol are combined in an aqueous fluid with
a poorly water soluble chemical azole compound, such as
metronidazole to form an aqueous solution. The total concentration
of the polyol and the polyol ether, the polyol and the low carbon
organic alcohol, the polyol ether and the low carbon organic
alcohol, or the polyol, the polyol ether, and the low carbon
organic alcohol that is combined in the aqueous fluid is that which
is sufficient to provide a synergistic increase in the solubility
of the azole chemical compound in the aqueous fluid in the absence
of any two or more of a polyol, a polyol ether, and a low carbon
organic alcohol.
[0015] The absolute and relative concentrations of the polyol,
polyol ether, and low carbon organic alcohol in the aqueous fluid
may be varied, if desired, in order to obtain a particular increase
in solubility of the azole compound in they aqueous fluid. It is
expected, however; that any amount and any ratio of two or more of
a polyol, polyol ether, and low carbon organic alcohol will result
in a synergistic increase in solubility of azole compounds in the
mixed solvent system compared to the solubility of the azole
compounds in an aqueous fluid lacking two or more of a polyol, a
polyol ether, and a low carbon organic alcohol.
[0016] The aqueous fluid may contain, in addition to the above
components, additional components such as, but not limited to,
additional solubility enhancing agents such as one or more of a
cyclodextrin, niacin, and niacinamide, gelling agents such as a
carbomer or a cellulosic polymer, preservatives, chelating agents,
pH adjusting agents and buffers.
[0017] The aqueous solution of the invention may constitute the
internal aqueous phase of a water-in-oil emulsion or the external
aqueous phase of an oil-in-water emulsion. Methods of making such
emulsions are well known in the art.
[0018] The solutions of the invention, including gels, may be used
for the topical treatment of dermatologic or mucosal disorders that
are responsive to therapy with azole compounds such as
metronidazole. In accordance with the method of treatment of the
invention, a stable aqueous solution as described herein containing
an azole compound and two or more of a polyol, a polyol ether, and
a low carbon organic alcohol is topically applied to skin or
mucosal surfaces in need of such therapy. Examples of disorders
that are suitably treated in accordance with the invention include
inflammatory lesions on skin or mucosa, such as oral or vaginal
mucosa, diabetic foot ulcers, and certain infectious diseases that
are responsive to topical therapy. A particular disorder that may
be treated with the method of the invention is rosacea, also known
as acne rosacea.
[0019] Preferably, the dissolved concentration of the azole
compound in the pharmaceutical formulation of the invention is
sufficient so that application once daily is effective to
ameliorate the disorder. For example, with metronidazole,
concentrations of about 1% or higher provide effective treatment
when applied only once daily. At concentrations below 1.0%, it is
recommended to apply a metronidazole formulation at least twice
daily. The solution containing metronidazole or other azole
compound is applied on a daily basis, one or more times per day,
for a time sufficient to produce an amelioration or a cure of the
disorder. In certain chronic disorders, the solution may be applied
one or more times daily for a prolonged period to prevent worsening
of the disorder.
[0020] The invention is further illustrated in the following
iron-limiting examples. In the examples, propylene glycol is
utilized as a representative polyol, Transcutol.RTM. is utilize as
a representative polyol ether; benzyl alcohol is utilized as a
representative low carbon organic alcohol, and metronidazole is
utilized as a representative azole chemical compound. It is
understood, however, that other polyols, polyol ethers, low carbon
organic alcohols, and azole compounds may be substituted in place
of the exemplified propylene glycol, Transcutol.RTM., benzyl
alcohol, and metronidazole.
Example 1
Procedure for Determining Solubility of Metronidazole
[0021] In the Examples that follow, solubility of metronidazole was
determined as follows.
[0022] An appropriate amount of each vehicle component was weighted
into a 20 ml scintillation vial and the components were shaken
until a clear solution was obtained. Metronidazole was then added
to the solution and the vials were shaken overnight at room
temperature to obtain a saturated solution of metronidazole. The
solution was filtered to remove any undissolved metronidazole and
the, concentration of metronidazole dissolved in the solution was
determined by HPLC. The solutions were physically stable at room
temperature for at least two weeks, with no precipitation
formation.
Example 2
Solubility of Metronidazole in Single Vehicles
[0023] The procedure of Example 1 was performed to determine the
solubility of metronidazole in a single vehicle solvent selected
from water, ethoxydiglycol, benzyl alcohol, and propylene glycol.
The results are shown below in Table 1.
TABLE-US-00001 TABLE 1 Solvent Metronidazole Solubility % w/w Water
0.87 Ethoxydiglycol 2.47 Benzyl Alcohol 6.23 Propylene Glycol
1.88
Example 3
Solubility of Metronidazole in Multiple Vehicle System Containing
Water, a Polyol, a Polyol Ether, and a Low Carbon Organic
Alcohol
[0024] The procedure of Example 1 was performed to determine the
solubility of metronidazole in a multiple vehicle solvent system
containing water, ethoxydiglycol, benzyl alcohol, and propylene
glycol. The composition of the solvent system is shown below in
Table 2.
TABLE-US-00002 TABLE 2 Components Amount % w/w Ethoxydiglycol 29.8
Benzyl Alcohol 5.0 Propylene Glycol 10.0 Water 55.2
[0025] Based on the solubility of metronidazole in each component
of the multi-component vehicle system, the anticipated solubility
of metronidazole in this vehicle was calculated to be 1.716% w/w.
The calculations are shown in Table 3, where the solubility of each
component in isolation times the concentration in the vehicle blend
provides the anticipated (additive or calculated) solubility.
TABLE-US-00003 TABLE 3 Metronidazole solubility in Fractional
individual Anticipated Component Amount component % w/w solubility
% w/w Ethoxydiglycol 0.298 2.47 0.736 Benzyl Alcohol 0.050 6.23
0.312 Propylene 0.100 1.88 0.188 Glycol Water 0.552 0.87 0.480
Total 1.000 1.716
[0026] Although, as shown in Table 3, the anticipated solubility of
metronidazole in the multiple vehicle system was calculated to be
1.716% w/w, the actual solubility of metronidazole in this
multi-component vehicle system was experimentally determined, by
HPLC, to be 2.54% w/w, see Table 6, Blend #1, in Example 5 below.
The solubility of metronidazole in the multi-component vehicle
system was 48.5% higher than expected if the contribution to
solubility by each of the components was additive. Thus, the
results of this study establish that the combination of water,
polyol, polyol ether, and low carbon organic alcohol provides a
synergistic effect on the solubility of metronidazole in an aqueous
vehicle.
Example 4
Solubility of Metronidazole in Multi-Component Vehicle System
Containing Water, a Polyol, a Polyol Ether, and a Low Carbon
Organic Alcohol
[0027] The procedure of Example 3 was repeated except that the
concentration of benzyl alcohol in the aqueous fluid was reduced by
50% and the concentration of water in the fluid was increased
accordingly. The composition of the solvent system is shown in
Table 4.
TABLE-US-00004 TABLE 4 Components Amount % w/w Ethoxydiglycol 29.9
Benzyl Alcohol 2.5 Propylene Glycol 10.1 Water 57.5
[0028] Based on the solubility of metronidazole in each component
of the multiple vehicle system, the anticipated solubility of
metronidazole in this system was calculated to be 1.582% w/w. The
calculations are shown in Table 5.
TABLE-US-00005 TABLE 5 Metronidazole solubility in Fractional
individual Anticipated Component Amount component % w/w solubility
% w/w Ethoxydiglycol 0.299 2.47 0.739 Benzyl Alcohol 0.025 6.23
0.156 Propylene Glycol 0.101 1.88 0.190 Water 0.575 0.87 0.500
Total 1.000 1.584
[0029] In the solution containing the components shown in Table 4,
the solubility of metronidazole in the multi-component vehicle
system was experimentally determined, by HPLC, to be 2.07% w/w, see
Table 6, Blend #2, in Example 5 below. The solubility of
metronidazole in this multi-component vehicle system was 31.0%
higher than expected if the contribution to solubility by each of
the components was additive.
Example 5
Solubility of Metronidazole in a Variety of Concentrations of the
Multi-Component Solvent System
[0030] The procedure of Example 1 was utilized to create a variety
of multi-component solvent systems containing water, a polyol, a
polyol ether, and a low carbon organic alcohol. The anticipated
calculated solubility of metronidazole in each system was
calculated and the actual solubility of metronidazole in each
system was determined by HPLC as described in Example 1. Blends #1
and 2 are the solvent systems of Example, 3 and 4, respectively.
The results are shown in Table 6.
TABLE-US-00006 TABLE 6 Theoretical Actual Solubility Blend Benzyl
Propylene Solubility Solubility Increase # Water Transcutol .RTM.
alcohol glycol (% w/w).sup.1 (% w/w).sup.2 %.sup.3 1 55.2 29.8 5.0
10.0 1.71 2.54 48.5* 2 57.5 29.9 2.5 10.1 1.58 2.07 31.0* 3 60.0
30.0 0.0 10.0 1.45 1.66 1.45* 4 65.1 29.9 0.0 5.0 1.4 1.48 5.7 5
65.0 30.0 5.0 0.0 1.62 2.27 40.1* 6 71.0 29.0 0.0 0.0 1.33 1.35 1.5
7 73.1 16.9 0.0 10.0 1.24 1.22 (1.6) 8 74.1 16.0 5.0 5.0 1.44 1.96
36.1* 9 74.5 12.9 2.5 10.1 1.31 1.54 17.6* 10 74.9 23.0 2.1 0.0
1.35 1.66 23.0* 11 81.4 11.1 2.5 5.0 1.23 1.43 16.3* 12 83.9 1.1
5.1 10.0 1.26 1.72 36.5* 13 84.9 0.0 5.1 10.0 1.24 1.66 33.9* 14
89.0 11.0 0.0 0.0 1.04 1.01 (2.9) 15 89.9 0.0 0.0 10.1 0.97 0.93
(4.1) 16 91.5 3.4 5.1 0.0 1.2 1.56 30.0* 17 92.5 0.0 2.5 5.1 1.05
1.20 14.3* 18 95.0 0.0 0.0 5.0 0.92 0.91 (1.1) 19 95.0 0.5 4.5 0.0
1.12 1.44 28.6* 20 97.6 0.0 2.4 0.0 1.00 1.09 9.0 .sup.1Theoretical
(anticipated) solubility is based on the assumption that each
solvent's contribution to overall solubility is additive and is
calculated from the determined solubility of metronidazole due to
each component as shown in Table 1 in Example 2 .sup.2Actual
solubility of metronidazole was obtained by HPLC analysis
.sup.3Actual solubility minus theoretical solubility divided by
theoretical solubility and multiplied by 100. *Solubility increase
or (decrease) greater than +/-10% is considered to be
significant.
[0031] The data in Table 6 establishes the synergism obtained by
combination of any two of a polyol, a polyol ether, and a low
carbon organic alcohol. The highest percentage increases in
solubility were obtained in solvent systems that included a low
carbon organic alcohol. No increase in solubility above the
calculated solubility was obtained when utilizing a solvent system
containing water and only one ether solvent.
Example 6
Metronidazole 1.5% Gel
[0032] An exemplary gel pharmaceutical composition containing
metronidazole at a concentration of 15% w/w was produced by
combining the following components, as shown below in Table 7.
TABLE-US-00007 TABLE 7 Components % w/w Metronidazole 1.50
Propylene glycol 5.00 Niacinamide 3.00 Beta-Cyclodextrin 1.00
Methylparaben 0.15 Propylparaben 0.05 EDTA disodium 0.05 Transcutol
.RTM. P 15.00 Benzyl alcohol 1.00 Carbopol .RTM. Ultrez 10 0.50 25%
Triethanolamine q.s. pH 6.0 10% HCl solution q.s. pH 6.0 Purified
water q.s. 100.00
[0033] The gel composition was made by combining metronidazole,
propylene glycol, niacinamide, beta-cyclodextrin, methylparaben,
propylparaben, EDTA disodium, Transcutol P, and benzyl alcohol in a
manufacturing vessel. These components were mixed while heating to
65.degree. C. until a clear solution was obtained. After removal
from the heat source, the gelling agent, Carbopol.RTM. Ultrez 10
(Lubrizol Corp., Wickliffe, Ohio) was added with continuous mixing
until dispersed into the mixture. Mixing was continued until a
homogenous gel was formed, and the system reached room temperature.
The pH was then adjusted to 6.0.+-.0.3 with triethanolamine or HCl
solution.
Example 7
Metronidazole 1.25% and 1.5% Gels
[0034] Exemplary gel pharmaceutical compositions containing
metronidazole at a concentration of 1.25% w/w and 1.5% w/w were
produced according to the method of Example 6 by combining the
following components, as shown below in Tables 8 and 9,
respectively. The solutions were determined to be stable with no
evidence of precipitate formation following storage at room
temperature for two weeks or at a temperature of 5.degree. C. for
one week.
TABLE-US-00008 TABLE 8 Components % w/w Metronidazole 1.25
Propylene glycol 5.00 Methylparaben 0.15 Propylparaben 0.05 EDTA
sodium 0.05 Ethoxydiglycol 25.00 Benzyl alcohol 1.00 Carbopol .RTM.
Ultrez 10 0.50 25% Triethanolamine q.s. pH 6.0 10% HCl solution
q.s. pH 6.0 Purified water q.s. 100.00
TABLE-US-00009 TABLE 9 Components % w/w Metronidazole 1.50
Propylene glycol 10.00 Methylparaben 0.15 Propylparaben 0.05 EDTA
sodium 0.05 Ethoxydiglycol 25.00 Benzyl alcohol 2.00 Carbopol .RTM.
Ultrez 10 0.50 25% Triethanolamine q.s. pH 6.0 10% HCl solution
q.s. pH 6.0 Purified water q.s. 100.00
Example 8
Metronidazole 1.25% and 1.5% Gels
[0035] Exemplary gel pharmaceutical compositions containing
metronidazole at a concentration of 1.25% w/w and 1.5% w/w were
produced according to the method of Example 6 by combining the
following components, as shown below in Tables 10 and 11,
respectively. The solutions were determined to be stable with no
evidence of precipitate formation following storage at room
temperature for two weeks or at a temperature of 5.degree. C. for
one week.
TABLE-US-00010 TABLE 10 Components % w/w Metronidazole 1.25 PEG 400
5.00 Methylparaben 0.15 Propylparaben 0.05 EDTA sodium 0.05
Ethoxydiglycol 35.00 Ethanol 3.00 Carbopol .RTM. Ultrez 10 0.50 25%
Triethanolamine q.s. pH 6.0 10% HCl solution q.s. pH 6.0 Purified
water q.s. 100.00
TABLE-US-00011 TABLE 11 Components % w/w Metronidazole 1.50
Hexylene glycol 5.00 Methylparaben 0.15 Propylparaben 0.05 EDTA
sodium 0.05 Ethoxydiglycol 35.00 Ethanol 3.00 Carbopol .RTM. Ultrez
10 0.50 25% Triethanolamine q.s. pH 6.0 10% HCl solution q.s. pH
6.0 Purified water q.s. 100.00
[0036] Various modifications of the above described invention will
be evident to those skilled in the art. It is intended that such
modifications are included within the scope of the following
claims.
* * * * *